Embedded Files
Pathology and Anticatalysis treatment of exasperated COVID-19
Pathology and Anticatalysis treatment of exasperated COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces immune-mediated diseases, which pathophysiology involves the angiotensin-converting enzyme 2 (ACE2) receptor, Toll-like receptor 4 (TLR4) pathway, neuropilin‑1 pathway, inflammasome activation pathway, sterile alpha motif (SAM) and histidine-aspartate domain (HD)-containing protein 1 (SAMHD1) tetramerization pathway, cytosolic DNA sensor cyclic-GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway, spike protein/inflammasome-genetic pathway, and immunological memory engram pathway. Therefore, it is necessary to prescribe anticatalytic treatments for type I interferonopathies to alleviate the exacerbated COVID-19 and take the lag time to activate innate or adaptive immune cell reactions.
ClinicalTrials.gov Identifier: NCT04918914
https://clinicaltrials.gov/ct2/show/NCT04918914
The goal of treatment is to reduce the severity of the infectious disease to the level of the flu.
ClinicalTrials.gov Identifier: NCT04935476
https://clinicaltrials.gov/ct2/show/NCT04935476
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19 (DAP-CORONA)
Page updated
Report abuse